Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Antiangiogenic Treatment Diminishes Renal Injury and Dysfunction via Regulation of Local AKT in Early Experimental Diabetes

  • The PLOS ONE Staff

There are errors in the legends of Figures 1, 3, and 4. Please read the scale bar ‘50 µm' instead of ‘50 mm' in Figure Legends 1, 3, and 4. The authors have provided the correct versions of Figure Legends 1, 3, and 4 here.

Figure 1. VEGF-A siRNAs cause upregulation of phosphorylated Thr308-AKT and nephrin in podocytes in high glucose. (A) Upregulated pAKT (T308) while (B) no effects on pAKT (S473) in podocytes mediated by VEGF-A_siRNA#1 and #2 (immunofluorescence, scale bar 50µm). (C) Upregulated nephrin mRNA while no effects on total AKT mediated by VEGF-A_siRNA#1 and #2 as shown in quantitative real time RT-PCR. (D) Upregulated protein levels of pAKT (T308) and nephrin, while no effects on total AKT and pAKT (S473) mediated by VEGF-A_siRNA#1 and #2, as shown in Western blot analysis and (E) the relative quantification normalized by β-actin expression (*P<.05 vs. NT_siRNA). VEGF-A: vascular endothelial growth factor-A; pAKT (T308): phosphorylated Thr308-AKT; pAKT (S473): phosphorylated Ser473-AKT; NT_siRNA: non-targeting small interference RNA.

Figure 3. MK-2206 inhibits AKT and upregulates VEGF-A in podocytes. (A) Upregulated VEGF-A and downregulated pAKT (T308) and (B) pAKT (S473) in podocytes with MK-2206 treatment (immunofluorescence, scale bar 50µm). (C) Inhibition of pAKT (T308) and pAKT (S473) and increased VEGF-A by MK-2206 as shown in Western blot analysis and (D) the relative quantification normalized by β-actin expression (*P<.05 vs. vehicle). DMSO: dimethyl sulfoxide; pAKT (T308): phosphorylated Thr308-AKT; pAKT (S473): phosphorylated Ser473-AKT.

Figure 4. MK-2206 inhibits AKT and upregulates VEGF-A in NRK-52E cells. (A) Upregulated VEGF-A and downregulated pAKT (T308) and (B) pAKT (S473) in NRK-52E cells with MK-2206 treatment (immunofluorescence, scale bar 50µm). (C) Inhibition of pAKT (T308) and pAKT (S473) and increased VEGF-A by MK-2206 as shown in Western blot analysis and (D) the relative quantification normalized by β-actin expression (*P<.05 vs. vehicle). pAKT (T308): phosphorylated Thr308-AKT; pAKT (S473): phosphorylated Ser473-AKT.

Reference

  1. 1. Bai X, Li X, Tian J, Zhou Z (2014) Antiangiogenic Treatment Diminishes Renal Injury and Dysfunction via Regulation of Local AKT in Early Experimental Diabetes. PLoS ONE 9(4): e96117

Citation: The PLOS ONE Staff (2014) Correction: Antiangiogenic Treatment Diminishes Renal Injury and Dysfunction via Regulation of Local AKT in Early Experimental Diabetes. PLoS ONE 9(7): e103926. https://doi.org/10.1371/journal.pone.0103926

Published: July 29, 2014

Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.